Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Influence of unsteady pressure-flow conditions on strength of steel pipelines with volumetric defects reinforced by composite sleeves

Autor: Uilhoorn Ferdinand, Witek Maciej

Publikováno v: E3S Web of Conferences, Vol 137, p 01043 (2019)

Structural integrity and risk management have a wide interest because of its practical applications, such as oil and gas pipelines, piping systems under pressure in power stations, urban water, and heating networks. The main goal of this paper is two

Externí odkaz: https://doaj.org/article/e422fbd21e834f2d83316adc890bfee8

Correlations and ridge in pPb collisions in the LHCb Experiment

Autor: Witek Mariusz

Publikováno v: EPJ Web of Conferences, Vol 141, p 01007 (2017)

The LHCb experiment, besides its main programme concerning flavour physics performs also very well as a general purpose forward detector, covering the pseudo-rapidity range from 2.0 to 5.0. Exploiting the experiment’s unique geometry, the LHCb coll

Externí odkaz: https://doaj.org/article/df08cc97d46c4ac9be9cba0db870945c

Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study

Autor: Shen Xinglei, Andrews David W, Sergott Robert C, Evans James J, Curran Walter J, Machtay Mitchell, Fragoso Ruben, Eldredge Harriet, Champ Colin E, Witek Matthew, Mishra Mark V, Dicker Adam P, Werner-Wasik Maria

Publikováno v: Radiation Oncology, Vol 7, Iss 1, p 225 (2012)

Abstract Background Skull base meningiomas commonly present with cranial neuropathies. Fractionated stereotactic radiation therapy (FSRT) has been used to treat these tumors with excellent local control, but rates of improvement in cranial neuropathi

Externí odkaz: https://doaj.org/article/5b16619718db436cb61fac13740dd62f

BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma.

Autor: Rashid A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Wesson W; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Snyder J; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Venkatesh P; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Shune L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Witek MA; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Soper SA; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS., Cui W; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS. Electronic address: nahmed5@kumc.edu.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Oct 11. Date of Electronic Publication: 2024 Oct 11.